Tom Ichim, Ph.D.

Thomas Ichim, Ph.D, is a trusted Scientific Advisor to FibroBiologics, bringing over 20 years of broad biotechnology experience to the company. His experience includes the filing and prosecuting of over 100 patents filed and issued, obtaining regulatory approvals, conducting clinical trials, and successfully providing a return to investors by taking companies public or the selling of companies. He has been published in 110 peer-reviewed journals and publications.                                                            

He co-founded bioRASI, a fully integrated CRO that made the INC 500 list for fastest-growing companies in the USA. He subsequently joined Medistem Inc., a stem cell company that was purchased by the NYSE traded company Intrexon. Prior to bioRASI, he co-founded Batu Biologics, a cancer vaccine, and Regen BioPharma and Creative Medical Technology Holdings, both of which he successfully took public. He is peer-reviewed for multiple scientific journals and sits on the Editorial Board of the Journal of Translational Medicine. He is also the author and co-author of multiple book chapters and three textbooks.